Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up

Abstract

Background

Targeted therapies are of increasing clinical importance and classic radiologic therapy response-criteria often fail to detect early therapeutic response or failure. For hepatocellular carcinoma (HCC), this is of major importance as therapeutic options are limited.

Purpose

To investigate the impact of sorafenib-treatment on intralesional perfusion using perfusion computed tomography (PCT) in HCC and to correlate the observed changes with mRECIST and the course of serum alpha-fetoprotein (AFP) for identification of their prognostic value.

Material and Methods

PCT was performed before and after two months of sorafenib treatment in 28 consecutive HCC patients and AFP levels were registered. Changes in tumor perfusion parameters blood flow (BF), blood volume (BV), mean transit time (MTT), volume transfer constant (K^trans), arterial liver perfusion (ALP), and hepatic perfusion index (HPI) were registered in one target lesion. mRECIST measurements were performed at baseline and after two and four months during sorafenib treatment.

Results

According to mRECIST, after two months of treatment, all patients showed stable disease (SD), whereas after four months, 13 patients (46%) showed SD and 15 patients (54%) showed progressive disease (PD). A significant decrease was found in perfusion parameters BF, BV, K^trans, ALP, and HPI in patients with SD as well as a significant increase in MTT (P < 0.05) after two months compared to baseline, while patients with PD showed a significant increase in HPI, BF, and BV. There were no correlations between AFP and mRECIST or perfusion parameters.

Conclusion

Decreased intralesional BF and HPI after two months of sorafenib treatment predicts disease stabilization after four months, whereas AFP dynamics were of limited value.

Keywords

Liver hepatocellular carcinoma (HCC)anti-angiogenic treatment computed tomography (CT)Abdomen/GI molecular imaging

Get full access to this article

View all access options for this article.

References

Jemal

Bray

Center

et al.

Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

Llovet

Ricci

Mazzaferro

et al.

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.

Chang

Adnane

Trail

et al.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561–574.

Villanueva

Newell

Chiang

et al.

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55–76.

Wilhelm

Adnane

Newell

et al.

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129–3140.

Keating

. Sorafenib: a review in hepatocellular carcinoma. Target Oncol 2017; 12: 243–253.

Sacco

Faggioni

Bargellini

et al.

Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis 2013; 45: 776–781.

Bruix

Gores

Mazzaferro

. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844–855.

Wilhelm

Carter

Tang

et al.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.

10.

Edeline

Boucher

Rolland

et al.

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118: 147–156.

11.

Arizumi

Ueshima

Takeda

et al.

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 2014; 49: 1578–1587.

12.

Lencioni

Llovet

. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60.

13.

Jiang

Kambadakone

Kulkarni

et al.

Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47: 11–17.

14.

Zhu

Holalkere

Muzikansky

et al.

Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13: 120–125.

15.

Frampas

Lassau

Zappa

et al.

Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol 2013; 82: e205–211.

16.

Shao

Lin

Hsu

et al.

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590–4596.

17.

Spira

Fenchel

Lauer

et al.

Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18: 89–96.

18.

Vora

Zheng

Stadler

et al.

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717–725.

19.

Bruix

Sherman

. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.

20.

Horger

Lauer

Schraml

et al.

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9: 208–208.

21.

Bargellini

Scionti

Mismas

et al.

Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?

Oncology 2014; 86: 191–198.

22.

Colagrande

Regini

Taliani

et al.

Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7: 1041–1053.

23.

Kaufmann

Horger

Oelker

et al.

Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique. Eur J Radiol 2015; 84: 1029–1035.

24.

Sahani

Holalkere

Mueller

et al.

Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243: 736–743.

25.

Wang

Shi

Wang

et al.

Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. Br J Radiol 2014; 87: 20130695–20130695.

26.

Gordic

Puippe

Krauss

et al.

Correlation between dual-energy and perfusion CT in patients with hepatocellular carcinoma. Radiology 2016; 280: 78–87.

27.

Jelic

Group

EGW

. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 41–45.

28.

Chen

Liu

Chao

et al.

Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005; 22: 217–226.

29.

Personeni

Bozzarelli

Pressiani

et al.

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57: 101–107.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.25 MB